

Anna Skiada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9303260/publications.pdf>

Version: 2024-02-01

20
papers

4,210
citations

430874

18
h-index

752698

20
g-index

55
all docs

55
docs citations

55
times ranked

4211
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 934-943.	3.0	5
2	Global Cutaneous Mucormycosis: A Systematic Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 194.	3.5	28
3	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. <i>BMC Infectious Diseases</i> , 2021, 21, 309.	2.9	4
4	Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 616.	3.5	40
5	Epidemiology and Diagnosis of Mucormycosis: An Update. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 265.	3.5	381
6	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1185-1191.	6.0	46
7	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
8	Treatment Outcomes of Colistin- and Carbapenem-resistant <i>Acinetobacter baumannii</i> Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 769-776.	5.8	83
9	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 391-400.	9.1	400
10	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1815-1823.	5.8	29
11	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <i>Haematologica</i> , 2017, 102, 433-444.	3.5	468
12	Rare fungal infectious agents: a lurking enemy. <i>F1000Research</i> , 2017, 6, 1917.	1.6	24
13	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. <i>BMJ Open</i> , 2016, 6, e009956.	1.9	41
14	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. <i>BMC Infectious Diseases</i> , 2016, 16, 667.	2.9	109
15	Carbapenemase-producing <i>Klebsiella pneumoniae</i> bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 335-339.	2.5	61
16	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). <i>Haematologica</i> , 2013, 98, 492-504.	3.5	282
17	Cutaneous mucormycosis. <i>Skinmed</i> , 2013, 11, 155-9; quiz 159-60.	0.0	25
18	Global epidemiology of cutaneous zygomycosis. <i>Clinics in Dermatology</i> , 2012, 30, 628-632.	1.6	89

#	ARTICLE	IF	CITATIONS
19	Epidemiology and Clinical Manifestations of Mucormycosis. <i>Clinical Infectious Diseases</i> , 2012, 54, S23-S34.	5.8	1,061
20	Adaptive resistance to cationic compounds in <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 187-193.	2.5	64